Clinomics is at the forefront of precision medicine, focusing on genome-based healthcare solutions aimed at enhancing human health and longevity. One of their key technologies is the CD-Prime platform, which utilizes liquid biopsy to detect specific cancer genome variants through a simple blood test. This innovative approach facilitates early cancer diagnosis and management, allowing for timely interventions. Additionally, Clinomics offers personalized healthcare by sequencing individual genomes, leveraging advanced bioinformatics and multi-omics big data to analyze diseases and aging processes. 

The company employs next-generation sequencing (NGS) for tumor genetic analysis, enabling the identification of actionable gene mutations that inform tailored treatment plans for patients. Clinomics also emphasizes the importance of big data in genomics, providing optimized infrastructure solutions that include hardware, software, and a proprietary BioOS to process genomic data efficiently. By integrating cutting-edge technologies, including artificial intelligence, Clinomics is revolutionizing the field of genomic technology, ultimately striving to deliver personalized and effective medical care.

South Korea

Clinomics provides early diagnosis of cancer/diseases based on genome and pursues to overcome aging and diseases through liquid biopsy and Multi-Omics technology.COVID-19: EUA (02/2021)

Clinomics

Company Details